Iron Deficiency Anemia Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, iron deficiency anemia therapy market size in 2026 is estimated at USD 5.68 billion, growing from 2025 value of USD 5.38 billion with 2031 projections showing USD 7.46 billion, growing at 5.60% CAGR over 2026-2031.

This report is Segmented by Therapy Type (Oral Iron Therapy (Ferrous Salts, and More), and Parenteral Iron Therapy (Ferric Carboxymaltose, Ferric Derisomaltose and More)), Age Group (Pediatric, Adults and Geriatric), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Iron Deficiency Anemia Therapy Market Trends and Insights

Increasing Global Iron-Deficiency Anemia Prevalence

Nearly 29.9% of women aged 15-49 and 39.8% of children worldwide live with iron deficiency anemia, equating to close to 2 billion potential therapy candidates. National surveys in South and Southeast Asia place prevalence for women as high as 63% in the Maldives. Rapid urbanisation has shifted diets toward lower iron density, while infectious disease loads continue to impede absorption. The resulting clinical burden sustains baseline demand for the iron deficiency anemia therapy market, even before accounting for chronic disease comorbidities. Longer-term demographic trends indicate sustained growth in high-risk groups, meaning underlying prevalence will remain the most powerful volume driver across forecast years.

Integration of Iron Therapy into Standard Care Pathways for Chronic Diseases

Cardiology, nephrology, and oncology guidelines now mandate ferritin screening and proactive replenishment, materially enlarging the treated population. The IRONMAN trial confirmed significant haemoglobin gains among heart-failure patients receiving ferric derisomaltose versus standard care. Similar momentum is visible in oncology, where intravenous ferric carboxymaltose achieved 52.1% haemoglobin response in solid-tumour patients compared with 32.9% for usual care. These recommendations create predictable, protocol-driven purchasing that supports premium formulations and stabilises reimbursement.

Safety and Tolerability Concerns Discouraging Long-Term Adherence

Gastrointestinal side effects still cause dropout for legacy ferrous salts, and hypersensitivity events, though rare, remain front of mind with intravenous products. Real-world audits show hypersensitivity in 3.1% of ferric derisomaltose recipients. Advanced oral options such as ferric maltol reduce discontinuations to under 5%, yet payer awareness is still catching up. The development of nano-encapsulated and transdermal delivery systems aims to remove these tolerability hurdles, but until such formats scale, adverse-event reluctance will weigh on uptake.

Other drivers and restraints analyzed in the detailed report include:

1. Government Anemia-Elimination Programmes
2. Digitalised IV-Dosing Protocols Reducing Clinic Time
3. Stringent Pharmacovigilance for Parenteral Iron

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Parenteral iron delivered 60.74% of iron deficiency anemia therapy market size in 2025, reflecting hospital reliance on total-dose infusions for severe cases. Total-dose options such as ferric carboxymaltose enable complete repletion in a single visit, which aligns with value-based care metrics that reward shorter length of stay. Ongoing hospital formulary expansions, alongside protocol integration for heart failure and oncology, anchor this dominance. However, raw-material tightness for ferric derisomaltose APIs has sparked selective shortages, highlighting latent vulnerability on the supply side.

Oral products post the swiftest expansion at a 7.42% CAGR. Ferric maltol and iron-whey-protein microspheres drive this upswing by slashing common gastrointestinal complaints that once undermined adherence. As adherence rates exceed 80% in recent trials, payers are reconsidering step-therapy rules that previously required failure on generic ferrous sulphate. This policy shift could accelerate volume migration toward premium oral brands over the forecast horizon, diversifying revenue streams inside the iron deficiency anemia therapy market.

Complete Report Scope:

• By Therapy Type
  • Oral Iron Therapy
    • Ferrous salts
    • Ferric and polysaccharide complexes
    • Enhanced-absorption or lipophilic
  • Parenteral Iron Therapy
    • Ferric carboxymaltose
    • Ferric derisomaltose
    • Iron sucrose
    • Others
• By Age Group
  • Pediatric
  • Adults
  • Geriatric
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America retained 37.10% of global revenue in 2025, buoyed by comprehensive reimbursement that covers both standard infusions and newer oral brands. Widespread adoption of single-visit ferric carboxymaltose and ferric derisomaltose regimens has reduced outpatient visits, freeing capacity in overstretched clinics. Canada's recent authorisation of ferric carboxymaltose for paediatric use extends addressability across the life course. Mexico's public-health insurers are piloting bundled anaemia management packages, though infrastructure limits infusion penetration outside metropolitan hubs.

Asia Pacific posts the fastest regional CAGR at 7.37%. Japan showcases sophisticated dosing algorithms that have shifted clinicians from saccharated ferric oxide to ferric carboxymaltose for efficiency gains. Australia's primary-care lobby estimates Medicare coverage for GP-led infusions could save USD 124 million in system costs, a proposal now under active review.

Europe maintains steady expansion on the back of guideline harmonisation and supply-security strategies that favour multiple API sources. Germany, France, and the Nordic markets deploy national registries to monitor infusion safety, reinforcing physician confidence in parenteral solutions. Eastern European countries, supported by EU health-equity funds, are scaling up paediatric supplement programs, creating new frontiers for the iron deficiency anemia therapy market even as mature Western states focus on chronic-disease integration.

1. Abbvie
2. Akebia Therapeutics
3. AMAG (-Covis)
4. Daiichi Sankyo
5. Pharmacosmos
6. Sanofi
7. Johnson & Johnson
8. Fresenius SE
9. Vifor Pharma
10. Rockwell Medical
11. Shield Therapeutics
12. American Regent
13. Nicholas Piramal
14. Cosmo Pharma
15. PharmaNutra
16. Cipla
17. Alkem Laboratories

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support